Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Sanofi ( (SNY) ) has shared an update.
In February 2025, Sanofi announced that the FDA has accepted for priority review its supplemental biologics license application for Dupixent, aimed at treating bullous pemphigoid, a chronic and debilitating skin disease. If approved, Dupixent would be the first targeted therapy for this condition in the United States, potentially improving treatment outcomes for approximately 27,000 affected adults. The acceptance is based on positive pivotal trial results demonstrating significant improvements in disease remission. Additionally, Sanofi and CD&R signed a share purchase agreement for Opella, further indicating strategic corporate maneuvers to enhance Sanofi’s market positioning and operational capabilities.
More about Sanofi
Sanofi is a global healthcare company focused on improving people’s lives through innovative medicines and vaccines. It operates across various therapeutic areas, including atopic dermatitis, asthma, and chronic rhinosinusitis among others, and is known for its commitment to sustainability and social responsibility.
YTD Price Performance: 11.23%
Average Trading Volume: 2,488,214
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $135.6B
See more insights into SNY stock on TipRanks’ Stock Analysis page.
